Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
Trial Parameters
Brief Summary
This study was an open, single center, prospective cohort study design. Subjects with advanced gastric cancer who had received first-line chemotherapy (cohort 1) and systematic chemotherapy combined with immunotherapy (cohort 2) were included in this study. 20 cases were included in each population, and a total of 40 subjects were planned to be included.
Eligibility Criteria
Inclusion Criteria: 1. Age range: 18 to 75 years old, both male and female are acceptable; 2. Patients with gastric adenocarcinoma or gastroesophageal junction adenocarcinoma diagnosed by histology or cytology; 3. Gastric cancer patients who have previously received first-line systemic chemotherapy (queue 1) or systemic chemotherapy combined with immunotherapy (queue 2) for progression; For intervention group 2, the best response to first-line immunotherapy is CR or PR or SD ≥ 3 months; 4. According to the evaluation criteria for solid tumor efficacy 1.1 (RECIST v1.1), there should be at least one measurable lesion that has not received local treatment such as radiotherapy (lesions located within the previously irradiated area can also be selected as target lesions if progression is confirmed); 5. ECOG score: 0-1 point; 6. Expected survival period ≥ 12 weeks; 7. The main organ functions well and the laboratory test data meets the following standards: (1) Blood routine: absolute neutrop